Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Dirk_Thye
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
development of precision therapeutics
|
| gptkbp:formerName |
gptkb:Cortexyme,_Inc.
|
| gptkbp:foundedYear |
2012
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quince Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:stockSymbol |
QNCX
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_QNCX
|
| gptkbp:website |
https://www.quincetx.com/
|
| gptkbp:bfsParent |
gptkb:Cortexyme,_Inc.
|
| gptkbp:bfsLayer |
7
|